Latest revenue
—
as of 2025-12-31
Latest net income
$-12.9M
as of 2025-12-31
Net margin
—
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ARTL is heading?
Price · 5Y
Market data
Price feed temporarily unavailable for ARTL.
5-year trend
What this company does
Corporate Overview We incorporated in the State of Nevada on May 2, 2011, and are presently based in the County of San Diego, California. We are a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system (the “ECS”), a network of receptors and neurotransmitters that form a biochemical communication system throughout the body. Our product candidate pipeline broadly leverages leading scientific methodologies and balances risk across mechanisms of action and stages of development. Our programs represent a comprehensive approach in utilizing the power and…
AI summary unavailable — showing raw filing excerpt
Generated from ARTL's filing dated 2026-02-24
Key risks
You should consider carefully the following information about the risks described below, together with the other information contained in this Annual Report on Form 10-K and in our other public filings, in evaluating our business. If any of the following risks actually occur, our business, financial condition, results of operations, and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our Common Stock would likely decline. The Company has organized the description of these risks into groupings in an effort to enhance readability, but many of the risks interrelate or could be grouped or ordered in other ways, so no special…
AI summary unavailable — showing raw filing excerpt
Generated from ARTL's filing dated 2026-02-24
Profitability
Return on equity
1012.5%
394.4%Return on assets
-459.8%
119.8%Leverage
Debt / equity
-3.20×
596.9%Debt / assets
145.4%
271.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-3.0M | -24.7% | — |
Q4 2025 2025-12-31 | — | — | $-4.2M | -10.3% | — |
Q3 2025 2025-09-30 | — | — | $-3.1M | -175.6% | — |
Q2 2025 2025-06-30 | — | — | $-3.2M | -32.4% | — |
Q1 2025 2025-03-31 | — | — | $-2.4M | +4.5% | — |
Q4 2024 2024-12-31 | — | — | $-3.8M | — | — |
Q3 2024 2024-09-30 | — | — | $-1.1M | +53.8% | — |
Q2 2024 2024-06-30 | — | — | $-2.4M | -52.2% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ARTL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ARTL
Institutional value
$99.6K
Total shares held
98.5K
Distinct holders
10
+2 vs prior
As of
2025-12-31
Prior: 2025-09-30
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 33.6K | $41.0K | +33.4K (+15986.6%) | Added |
| 2 | TWO SIGMA INVESTMENTS, LP | 20.7K | $25.2K | — | New |
| 3 | VANGUARD GROUP INC | 14.0K | $17.1K | +0 (+0.0%) | No change |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 11.4K | $13.9K | — | New |
| 5 | Tower Research Capital LLC (TRC) | 1.9K | $2.3K | — | New |
| 6 | Virtu Financial LLC | 16.9K | $21 | — | New |
| 7 | BANK OF AMERICA CORP /DE/ | 17 | $21 | -5 (-22.7%) | Trimmed |
| 8 | ROTHSCHILD INVESTMENT LLC | 2 | $2 | +0 (+0.0%) | No change |
| 9 | OSAIC HOLDINGS, INC. | 1 | $1 | — | New |
| 10 | CWM, LLC | 1 | $0 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ARTL's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.